Miriam Campos-Ruiz

Miriam Campos-Ruiz

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2021 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
EAElisenda Alari-Pahissa
Elisenda Alari-Pahissa
MAMichelle Ataya
Michelle Ataya
IMIlias Moraitis
Ilias Moraitis
MCMiriam Campos-Ruiz
Miriam Campos-Ruiz
MAMireia Altadill
Mireia Altadill
MLMiguel López-Botet
Miguel López-Botet
Epstein Barr virus (EBV) causes a highly prevalent and lifelong infection contributing to the development of some malignancies. In addition to the key role played by T cells in controlling this pathogen, NK cells mediate cytotoxicity and IFNγ production in response to EBV-infected B cells in lytic cycle, both directly and through antibody (Ab)-dependent activation. We recently described that EBV-specific Ab-dependent NK cell interaction with viral particles (VP) bound to B cells triggered degranulation and TNFα secretion but not B cell lysis nor IFNγ production. In this report we show that NK cell activation under these conditions reduced B cell transformation by EBV. NK cells eliminated VP from the surface of B cells through a specific and active process which required tyrosine kinase activation, actin polymerization and Ca2+, being independent of proteolysis and perforin. VP were displayed at the NK cell surface before being internalized and partially shuttled to early endosomes and lysosomes. VP transfer was encompassed by a trogocytosis process including the EBV receptor CD21, together with CD19 and CD20. Our study reveals a novel facet of the antibody-dependent NK cell mediated response to this viral infection.

29 July 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
MCMiriam Campos-Ruiz
Miriam Campos-Ruiz
CGClara Flamarich Gol
Clara Flamarich Gol
AFAnabel Fernández-Navarro
Anabel Fernández-Navarro
SRSílvia Roure
Sílvia Roure
LMLaura Martin
Laura Martin
GFGema Fernández-Rivas
Gema Fernández-Rivas
Cryptosporidium spp. is an apicomplexan protozoan parasite associated with gastroenteritis in humans. In 2018, Spain showed 1511 confirmed cases, with a growing trend since 2014. Despite this fact, Cryptosporidium spp. is not usually routinely examined when a parasitological study is ordered, although accurate diagnosis is fundamental to prevent the spread of the illness. The main objectives of the present work is to demonstrate the circulation and to study the epidemiology of cryptosporidiosis in patients who were being tested for the presence of Cryptosporidium spp. parasites in the faeces in the Metropolitan North Area of Barcelona, Maresme, and Vallés Occidental using a two-step algorithm. The stool samples were analysed using the Cryptosporidium/Giardia spp. immunochromatographic test; the positive samples were visualised under a microscope using auramine staining. The proportion of Cryptosporidium spp. cases was around 2% in the studied patients, with a pronounced seasonal incidence peak in late summer–early autumn. In our cohort, weight loss was the main symptom related to confirmed cases. The mean age of confirmed patients was 19 years old, and they were younger than the unconfirmed group. Cryptosporidium spp. is one of the parasites that currently circulate in many areas in Europe. Prevalence must be taken into account for active searching.

28 November 2024 in Heliyon
Verified
Journal Article
Open access
MCMiriam Campos-Ruiz
Miriam Campos-Ruiz
JWJun Hao Wang-Wang
Jun Hao Wang-Wang
BRBelén Rivaya
Belén Rivaya
BRBeatriz Rodriguez-Ponga
Beatriz Rodriguez-Ponga
NLNoelia López
Noelia López
GFGema Fernández-Rivas
Gema Fernández-Rivas
Serological screening for Chagas disease (CD) in Latin American adults living in Europe is a cost-effective strategy for transmission prevention. The World Health Organization recommends two different serological tests including native and recombinant antigens for IgG detection. In Spain, most commercialized native tests require manual processing. We aimed to evaluate the sensitivity and specificity of the automated Vitros® Anti-T. cruzi native antigen-based test. A total of 556 serum samples were tested using two different tests: 1) our reference assay, a chemiluminescence immunoassay employing a recombinant multi-antigen protein (Liaison® XL Murex Chagas); 2) a chemiluminescence immunoassay with native antigen (Vitros® Anti-T. cruzi assay). Additionally, 180 samples were also processed by a manual indirect immunofluorescent assay (Chagas IFA). Sensibility, specificity and kappa index were calculated. Vitros® showed a kappa index of 0.94 (IC 95 %: 0.86–1.03) compared to Liaison® XL with a sensitivity of 93.6 % and specificity of 99.5 %. Compared to IFA, Vitros® showed a kappa index of 0.61 (IC 95 %: 0.47–0.76), sensitivity of 97.5 % and specificity of 70.37 %. Discrepant results were obtained mainly in treated patients. The Vitros® Anti-T. cruzi assay showed potential for implementation as an automated serological screening test, enhancing the diagnostic process in high-throughput microbiology laboratories.